Role of MEPARTRICIN (cas 11121-32-7) in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial
-
Add time:07/19/2019 Source:sciencedirect.com
ObjectivesTo verify the efficacy of MEPARTRICIN (cas 11121-32-7) versus placebo with regard to symptom improvement in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS) and to verify a relation between hormonal levels and clinical improvement in these patients.
We also recommend Trading Suppliers and Manufacturers of MEPARTRICIN (cas 11121-32-7). Pls Click Website Link as below: cas 11121-32-7 suppliers
Prev:Effects of MEPARTRICIN (cas 11121-32-7) on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats
Next:A double-blind study of the effects of MEPARTRICIN (cas 11121-32-7) in the treatment of obstruction due to benign prostatic hyperplasia) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- A double-blind study of the effects of MEPARTRICIN (cas 11121-32-7) in the treatment of obstruction due to benign prostatic hyperplasia07/21/2019
- Effects of MEPARTRICIN (cas 11121-32-7) on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats07/18/2019